

Investment Digest

Teaser

Longevity Industry 2021/Q2

Table of Contents

| | |
|---|-----|
| The Longevity Economy on a Global Scale | 3 |
| Global Longevity Ecosystem 2021 Mindmap | 6 |
| Top Companies by Investment and Investment Stage | 13 |
| Longevity Landscape Framework | 24 |
| Longevity Companies by Funding Level and Specialization | 36 |
| Top Investors in the Longevity Sector | 40 |
| Longevity Investors Landscape by Country (Mindmap) | 41 |
| Comparison analysis of Longevity Investment Funds | 44 |
| Longevity Governance and Budgeting | 52 |
| Healthcare Spending and Health-Adjusted Life Expectancy | 67 |
| Longevity-Focused Financial Institutions | 74 |
| Publicly Traded Longevity-Focused Companies | 89 |
| Clinical Trials | 111 |
| Key Takeaways | 125 |
| About Aging Analytics Agency | 130 |
| Disclaimer | 145 |

Longevity Investment Digest at a Glance


This Investment Digest summarizes key observations in the private equity and venture capital ecosystem of the rapidly evolving and exponentially growing Longevity Industry. In it, we have assembled information about key industry trends, more than 23,000 longevity companies, 50 leading investors, and more than 600 longevity-focused publicly traded corporations. We have also outlined major investment rounds and relevant R&D trends, illustrating the industry's traction and readiness of institutional investors (including top-tier financial institutions) to potentially acquire the most successful startups, such as AgeTech, Longevity Fintech, and Longevity Biomedicine.

The COVID-19 pandemic has given a boost not only to the growth of the biotech capital market, but also to the development of the longevity biomedicine sector, resulting in an increase of more than 30% (compared to the previous year). Though the growth in the longevity market exceeds that of in the biotech and financial services markets, it still remains pretty volatile. 15 longevity-focused companies launched their IPOs in 2021, whereas more than a thousand of them received private equity investments. Currently, the growth rate of the longevity market is comparable to that of the IT sector. Longevity is regularly picked as a major topic of interest for panel discussions and entire conference series by top-tier finance and business media brands, including The Economist, Financial Times, and Bloomberg.

To sum up, the Longevity industry is poised to witness a quantum leap in the near future, particularly because of the impact of Artificial Intelligence on biomedicine R&D and in light of the upcoming paradigm shift from treatment to prevention.

The Longevity Economy on a Global Scale

The Longevity Economy: Scale Projections, \$



The Longevity Economy's Scale Projections contains global healthcare spending affecting Longevity, the combined capitalisation of publicly listed Longevity companies, the capitalisation of Longevity-related insurance and reinsurance companies, banks and pension funds and privately held Longevity companies.

Not only does aging pose one of the most acute problems of our time - it also presents one of the most promising opportunities. Financial institutions, such as investment banks, pension funds, and insurance companies can either sink or swim when hit by the oncoming Silver Tsunami. Whether they will succeed in riding the wave or end up drowning under it will depend not only on their willingness to deploy new business models adapted to population aging and emerging industries of AgeTech, WealthTech, and Longevity Finance, but also on the quality of longevity analytics that they use to develop such business models.

We define the Longevity Industry as a combination of aging, advanced preventive precision biomedicine, AgeTech, relevant parts of national healthcare budgets, and the global financial industry related to such sub-industries.


Global Longevity Ecosystem 2021

23,000 Companies

9,000 Investors

1,000 Hubs

20 Sectors



| | |
|-------------|-----------|
| USA | UK |
| Canada | India |
| Japan | China |
| Sweden | Germany |
| Switzerland | Spain |
| CEE* | Singapore |
| Portugal | France |
| Brazil | Australia |
| MENA Region | EU |

* – Central and Eastern Europe

Global Longevity Ecosystem - 23,000 Companies by 20 Sectors



Geroscience



Longevity WealthTech



Space Medicine



Deep Diagnostics



Longevity Biomarkers



FinTech



Longevity FemTech



Regenerative Medicine



AI for Longevity



InsurTech



Advanced Cosmetics



P4 Medicine



NeuroTech



AgeTech



Clinical Data management



Longevity Gene Therapy



PharmTech



Wellness & Fitness



Telemedicine



Mental Health



Longevity Industry: Multi-Trillion Dollar Opportunity



“The one billion retired people globally are a multi-trillion dollar opportunity for business “

~ Dmitry Kaminskiy, [inverview in the Financial Times](#)

“We expect to add 1 billion older individuals in the next three to four decades, atop the more than 700 million older people we have today “

~ *International Monetary Fund*



Longevity Industry: Multi-Trillion Dollar Opportunity

The Global Longevity Market is Estimated at \$25 trillion in 2021

23,000+ companies

600+ corporations

9,000+ investors

1,000+ financial institutions

100+ governments

114 subsectors

The longevity market is not only limited to anti-aging applications of life sciences. It also includes some new sectors of the financial industry, as well as government projects (national longevity development plans); hence, its overall size potentially exceeds \$25 trillion. As the majority of full-blown longevity startups are quickly becoming mature companies, large institutional investors are making increasingly more investments into the industry and a full-fledged longevity infrastructure is emerging.

There are at least 600 publicly traded corporations that can be considered part of the Longevity industry.

Longevity Biomedicine, FinTech, and AgeTech industries include 23,000+ companies, 9,000+ investors, 14 sectors, and 114 subsectors.

The longevity Financial Industry includes 1,000+ corporations, 15 sectors, and 50 subsectors.

The Longevity Governance Landscape includes national healthcare budgets and development plans of at least 100 governments.

Note: Since there is no generally accepted methodology for their estimation, the numbers presented in the scheme are approximate.


The “7th Continent” of 1 Billion People in Retirement



There are more than 1 billion people aged 60 years and older in the world nowadays. In fact, there are so many of them that they can populate an entire '7th Continent'.
Not only do they wield immense purchasing power, but they also hold the largest amount of financial assets compared to other age groups.

Longevity and Silver Tsunami - Collision of Two Opposing MegaTrends


Two Opposed MegaTrends



Rapid progress in biomedicine has been mainly due to the advances in collection and analysis of data. The industry is poised to witness a quantum leap in the near future, particularly because of the impact made by Artificial Intelligence on biomedicine R&D and in light of the upcoming paradigm shift from treatment to prevention.

At the same time, the inevitable Silver Tsunami (demographic aging) places a major economic burden not only on the healthcare systems of developing nations, but also on major financial institutions, including pension funds, insurance companies, asset management firms and retail/private wealth banks. It is also expected to increase costs associated with old age.

AgeTech Industry Market Capitalisation



World AgeTech Industry Size Projections, current US \$

AgeTech Sector:

- Elderly Care
- FinTech
- m-Health
- Senior Living Communities
- Social and Communication Caregiving
- Independence
- Social Protection
- Cognitive Care

Estimated at \$25 trillion in 2021, the global longevity economy is growing steadily and expected to be worth \$35 trillion by 2026. By the most conservative estimates, it accounts for 20% of the global GDP. While the global Longevity Economy is projected to reach \$35 trillion by 2026, the Age-Tech segment alone is projected to reach \$2.7 trillion by 2025. This, in turn, implies an annual growth rate of 21% in the global Age-Tech market, which is attributable to the development of the elderly care sector enhanced by IT, FinTech, and other digital technologies.


Investment Landscape in 2021 at a Glance

In 2021, the global investments in longevity-focused companies totalled **\$39.54B**.

Some of the major deals included:

- **Noom**, a psychology-based digital health platform used to provide intelligent nutrition and exercise coaching, raised \$540M in Series F Round;
- **Ro** announced a \$500M Series D round in March 2021, which values the 3.5-year-old company at \$5 billion;
- **PharmEasy**, health tech startup offering services such as teleconsultation, medicine deliveries, and diagnostic test sample collection, raised \$500M Series F in July 2021 at \$4B valuation supported by seven private institutional investors;
- **Miaoshou Doctor**, a platform based in China for doctors and patients to communicate, raised \$466M (Series E Round)
- **Olive** in July 2021 doubled its valuation after raising a \$400M in Series H funding round. The US-based company passed a \$4B valuation.

Top-5 Investment deals



Longevity Landscape Framework

Geroscience R&D

Rejuvenation
Biotechnology

Basic Research on
Biology of Ageing

Geroprotectors

Regenerative
Medicine

Nutraceuticals

Gene Therapy

P4 Medicine

Personalized
Diagnostics

Personalized HALE
and QALE Estimation

Personalized
Prognostics

Personalized in vivo
and in silico Drug
Testing

Preventive Therapies

Participatory Medicine

AgeTech

NeuroTech

Cognitive
Enhancement

Smart Homes

NextGen Mobile Apps
for the Elderly

Continuing Education

Entertainment for the
Elderly

Longevity WealthTech

Financial Planning

Asset Management

Micro-Investments

Digital Brokers

AI-Driven Assistants

Long-Term Securities

Longevity Finance

Longevity Index Fund

Longevity Hedge Fund

Longevity Stock
Exchange

AgeTech Bank

Longevity Derivatives

Longevity Investment
Bank

Longevity Governance

Pension Plans

National Healthcare
Budgets

Longevity
Development
Strategies

Elderly Care Programs

National Insurance

Elderly Education

Longevity Financial Industry Framework

InsurTech

HALE/QALE-Based
Insurance

AI-Driven Insurance
Premium Calculation

NextGen Mobile Apps

Healthy Lifestyle
Bonuses

Big Data Actuarial
Models

Biological Age
Estimation

WealthTech

Robo-Retirement

Digital Brokers

Micro-Investments

Annuities

Long-Term Securities

AI-Driven Advisors

Longevity Asset Management

Novel Retirement Plans

Portfolio Management

FinTech for the Elderly

NextGen Mobile Apps for
the Elderly

Financial Planning

De-Risking

Novel Financial System

Longevity Index Fund

Longevity Hedge Fund

Strategies Diversification

AgeTech Bank

Longevity Derivatives


Pension Planning

Most Advanced Pension-Tech Companies **grandhood™**

Aging Analytics Agency has analyzed the most advanced pension-tech companies and concluded that the majority of them are based in the UK and EU.




Top 10 Longevity-Focused Companies by Investments in 2021



Half-year 2021 demonstrates the lasting trend of boosted growth of the biotech capital market and the development of the longevity sector. Pandemic has stimulated an increase in investments in the longevity industry, where total funding of top 10 Longevity-focused companies exceeds **\$10.78B** as of July 2021. Biogroup-LCD, the France-based private company, is the leader by the amount of total investments having raised a total of **\$3.03B** in funding over 4 rounds. PharmEasy and Ro are private companies which are listed above due to late-stage mega-rounds in 2021.

Financial Institutions Advancing the Longevity Industry

Cumulative Capitalization Dynamics in 2020-2021




Since Q1 2020 market downturn, 194 financial institutions have fully recovered by year-end and continued to grow in 2021.

The largest institutions by market capitalization are [Berkshire Hathaway](#), [JPMorgan Chase & Co.](#), [Bank of America](#), and [Wells Fargo & Co.](#)

Given that many longevity advancing financial institutions are included in the S&P 500, this chart represents the approximate dynamics of the whole stock market.

Top 10 Financial Institutions in 2021 (by Market Capitalization)



Top-300 Financial Institutions Advancing the Longevity Industry

105 Asset Management Firms



75 Banks



55 Insurance Companies



20 Reinsurance Companies



45 Pension Funds



Top-20 Financial Institutions by Stock Exchange

NYSE

US-Based

BH Berkshire Hathaway (BRK-B)
Market Cap: \$642B

AMERICAN EXPRESS American Express (AXP)
Market Cap: \$137B

citi Citigroup (C)
Market Cap: \$141B

JPMC & Co. JPMorgan Chase & Co. (JPM)
Market Cap: \$453B

B The Blackstone Group (BX)
Market Cap: \$138B

GS Goldman Sachs Group Inc. (GS)
Market Cap: \$133B

BAC Bank of America Corp. (BAC)
Market Cap: \$322B

MS Morgan Stanley (MS)
Market Cap: \$177B

WF Wells Fargo & Co. (WFC)
Market Cap: \$185B

Canada-Based

RY Royal Bank of Canada (RY)
Market Cap: \$143B

TD Toronto-Dominion Bank (TD)
Market Cap: \$120B

UK-Based

HSBC HSBC Holdings (HSBC)
Market Cap: \$113B

Australia (ASX)

Australia-Based

CBA Commonwealth Bank of Australia (CBA)
Market Cap: \$130B

China (SSE)

China-Based

PING AN Ping An Insurance (PNGAY)
Market Cap: \$148B

ACGBY Agricultural Bank of China (ACGBY)
Market Cap: \$158B

Hong Kong (HKEX)

China-Based

CHICHY China Construction Bank (CHICHY)
Market Cap: \$179B

CIHKY China Merchants Bank (CIHKY)
Market Cap: \$183B

BACHY Bank of China (BACHY)
Market Cap: \$130B

AAGIY AIA Group (AAGIY)
Market Cap: \$138B


LFC China Life Insurance (LFC)
Market Cap: \$103B

Longevity IPOs in 2021

| Name | Country | Funding Amount. M\$ | Last Funding Amount (M\$) | IPO Date | Capitalization (B\$) | ROA | ROE | Profit margin | Net income (M) |
|---------------------------|----------------|---------------------|---------------------------|------------|----------------------|----------|----------|---------------|----------------|
| Clover Health | USA | 1,325 | 400 | 08.01.2021 | 3.29 | 119.18% | -157.16% | 8.6% | -156.6 |
| Recursion Pharmaceuticals | USA | 465.3 | 239 | 16.04.2021 | 5.17 | -26.24% | -54.57% | -1498.16% | -99.3 |
| Sana Biotechnology | USA | 700 | 700 | 04.02.2021 | 2.95 | -25.46% | -80.76% | 0 | -285.3 |
| Century Therapeutics | USA | 410 | 160 | 18.06.2021 | 1.64 | -21.76% | - | 0 | -62.3 |
| HCW Biologics | USA | 39.2 | 6.16 | 19.07.2021 | 0.171 | -12.71% | -27.37% | -243.39% | -6.3 |
| Decibel Therapeutics | USA | 189.2 | 82.2 | 11.02.2021 | 0.179 | -40.48% | -145.27% | 0 | -38.7 |
| G Medical Innovations | USA | 350.1 | 20.5 | 24.06.2021 | 0.052 | -83.12% | -197.86% | 13.61% | 12.5 |
| Celularity | Cayman Islands | 290 | 250 | 19.07.2021 | 1.11 | -10.25% | -264.98% | 65.46% | -259.6 |
| Longeveron | USA | 8.9 | 3 | 11.02.2021 | 0.117 | -38.83% | -4914.7% | - | -6.6 |
| Biophytis | France | 16.1 | 0.6 | 15.02.2021 | 0.238 | -16.98% | - | 0 | -17.1 |
| Affirm Holdings | USA | 1520 | - | 13.01.2021 | 16.134 | -5.28% | -23.17% | -31.88% | -243 |
| Oscar Health | USA | 1,632.5 | 140 | 03.03.2021 | 3.617 | -13.89% | -101.75% | -58.28% | -397 |
| Hims & Hers Health | USA | 233.2 | 75 | 20.01.2021 | 1.521 | -9.92% | -37.41% | -37.12% | -63.5 |
| Cloud DX Inc | USA | 20.9 | 3.4 | 15.04.2021 | 19.75 | -136.12% | -181.69% | 0 | -4.5 |
| ATAI Life Sciences | Germany | 347.1 | 157 | 17.06.2021 | 2.41 | -166.56% | 194.39% | 0 | -185.5 |

Longevity Clinical Trials Market at a Glance

Preclinical Studies and Clinical Trials Market Size, 2020-2026



The global **Preclinical Studies and Clinical Trials Market Size** accounted for **\$48.8B in 2020** and is projected to grow an average **CAGR of 6%** from 2020 till 2026 to reach **\$70.5B**. Despite increasing interest in recent years, the industry remains underestimated and has high growth potential.

The key market drivers include **rising life expectancy and disposable income; increased R&D spending of new drugs** by pharmaceutical companies. Due to high competition, companies are looking to **diversify their product portfolio with specialty drugs**. Additional **demand for clinical and preclinical services arises** because more pharmaceutical companies outsource large parts of R&D, primarily to clinical research organizations, to reduce costs.

3.4%

Global GDP Growth
in 2021

3.7%

Global Spending Growth on
Pharma R&D in 2021

0.24%

Life Expectancy
Growth in 2021

Sources: Grand View Research, Statista, IMF, Macrotrends

Longevity Industry Big Data Analytical Dashboards

Dashboard Overview

Aging Analytics Agency is working on a sophisticated cloud-based engine designed for advanced market and business intelligence in various segments of the longevity industry. It includes a data mining engine, infrastructure for expert data curation, and advanced visualization dashboards, including mindmaps, knowledge graphs, and 3D visualizations. It also offers data-driven insights into the trends and companies in the longevity industry, SWOT analysis of the most promising entities and technologies, investment advisory, business and technical due-diligence.

| | | |
|--------------------|--|---|
| Matching tool | Machine learning for database extrapolation | Dynamic SWOT analysis representing evolution of a company |
| Companies database | Machine learning and deep neural networks for companies clusterization | Interactive industry mindmaps |
| Investors database | Machine learning for financial indicators predictions | Real-time financial data analytics platform for AI in pharma corporations |
| SWOT analysis | Interactive AI-based scenario analysis and financial planning | AI in pharma financial instruments analytics |

Database, AI and ML algorithms overview

| | |
|------------------|--|
| Parameters | 400 parameters with appropriate weights combined into 20 vectors |
| Data points | 8 000 000 data points which are being updated permanently |
| Algorithms | Deep neural networks, polynomial formulas with mathematical transformations, regression models |
| Data aggregation | Automatized parsing, extrapolation using machine learning, feedback from companies |

Who Can Benefit

- Investment institutions, funds, investment banks, family offices;
- Private and public companies in pharma/biotech space
- Research institutions, universities
- Technology vendors and contract research organizations
- Startup hubs, accelerators
- Consulting companies and agencies

Biomarkers of Longevity

Approved for Clinical Use - 41
 Research Use Only - 45
 Healthcare-Ready - 33

2nd edition.
 Current Status, 2021

Approved for Clinical Use

Healthcare-Ready
 (waiting for clinical approval)

Research Use Only



| Biomarker Panels | Digital Panel Platforms | Single Biomarkers |
|--|---|--|
| <p>Approved for Clinical Use</p> <ul style="list-style-type: none"> InsideTracker Inner Age, Ultimate Plan ROCC Immune-Frame, Adrenal Stress Profile GENOVA DIAGNOSTICS Comprehensive Adrenal Stress Profile ARIP B-Cell Memory and Naive Panel, Natural Killer Cell and Natural Killer T-Cell Panel Health + Ancestry Service, Carnitine Panel, Cytokine Panel, Hepatic Function Panel, Regulatory T-Cell Panel, Cytokine Panel FLUIDS IQ Adrenal Check, Adrenal Stress Profile, Advanced MethylDetox Profile, MethylDetox Profile + Telomere Length, AGE-Reader mu Test Oxidative Stress Analysis 2.0, Cytokine Panel, WellnessX Premium, Aging Therapeutic 1.0, 10 Hormone Saliva Test Kit, Anti-Aging #4 Comprehensive Blood and Urine Test Panel Female/Male Saliva Profile II - Test Kit for 6 Hormone Level Imbalances, Healthy Aging Panel (Comprehensive), GENOVA DIAGNOSTICS CardioGenomic Plus Profile, GENOVA DIAGNOSTICS ImmunoGenomic Profile, NeuroGenomic Profile, PhysioAge Biomarkers of Aging Test | <p>Digital Panel Platforms</p> <ul style="list-style-type: none"> Babylon Health Platform Ada Symptom Checker app CarePredict Platform Health Reviser Platform Google's DeepMind Health AI Platform Centers for Age Control AgeMeter | <p>Single Biomarkers</p> <ul style="list-style-type: none"> ARIP LABORATORIES CD4+ T-Cell Recent Thymic Emigrants ARIP LABORATORIES CD57+ NK Cells, Peripheral Blood by Flow Cytometry ARIP LABORATORIES CD21 (Dendritic Cell) by Immunohistochemistry |
| <p>Healthcare-Ready (waiting for clinical approval)</p> <ul style="list-style-type: none"> smartDNA smartGUT™ Microbiome Test, Genetic Age Test MICROBA Microba Insight™ GLYCANAGE GlycanAge Test TETRA Gut Microbiota Biohacker VIOME Viome Gut Intelligence™ Test TARNA toxomiRTM biomarkers of toxicity, osteomiRTM validated bone biomarkers, thrombomiRTM biomarkers of platelet function | <p>Digital Panel Platforms</p> <ul style="list-style-type: none"> nourish science Blood Chemistry Calculator zebo AI-Powered Radiology Assistant MediAge Biological Age Measurement System KenSci Platform Enlitic Platform Aging.AI YOUNG.AI PathAI Platform Buoy Health Platform Haut.AI PhotoAgeClock Haut.AI Skin Health zippango Digital Nutrition Platform | <p>Single Biomarkers</p> <ul style="list-style-type: none"> TruDiagnostic™ TruAge™ Epigenetic Test Kit Cell Science Systems Telomere Length Test ZYMO RESEARCH DNAge™ Epigenetic Aging Clock CHRONOMICS EpiHealth BioViva DNAge® Test EpiLiver TELOYEARS TeloYears + Advanced Ancestry Tests Epigenetic Age Analysis Version 2.0 EpiAging EpiSocialpsych Targeted Seq. for DNA Methylation Analysis X LIFE LENGTH Telomere Length and Biological Age Testing EpiBreast |
| <p>Research Use Only</p> <ul style="list-style-type: none"> QIAGEN Metabolism Panel, QIAGEN Immune Response Panel, QIAGEN Inflammation Panel, QIAGEN Organ Damage Panel, QIAGEN Cardiovascular II Panel, QIAGEN Cardiovascular I Panel, QIAGEN Oncology III Panel QIAGEN Oncology II Panel, QIAGEN Neurology Panel, QIAGEN Neuro Exploratory Panel, QIAGEN Cell Regulation Panel, QIAGEN Cardiovascular III Panel, humanMAP v.2.0, MetabolicMAP v.1.0 Amynad CardiovascularMAP v.3.0, Amynad DiscoveryMAP v.3.3 Panel, Amynad AngiogenesisMAP v.1.0, Amynad NeuroMAP v.1.0, Amynad Immunomap v.1.0, Amynad Explorer MAP v.1.0 InflammationMAP v.1.0, CytokineMAP B, Cytometry, Cytometry, Cytometry, Salivary Cytokine Panel LEGENDScreen Human PE Kit, LEGENDplex Human Th Cytokine Panel, Cytometry, Cytometry, Cytometry, Human v3 mRNA Assay | <p>Digital Panel Platforms</p> <ul style="list-style-type: none"> PROSCIA Proscia Platform Better Therapeutics Platform freemome Freemome Platform Tempus Platform BenevolentAI BenevolentAI Platform ICabonX Platform | |

Tangible Metrics to De-Risk Investments in Longevity Startups

Investment decisions practices in the longevity industry can be essentially enhanced through the application of the biomarkers of aging. Concrete and precise metrics of human aging can assist investors in differentiating between overvalued hype-driven startups without any proofs of success in fighting human aging and promising businesses which are producing tangible anti-aging results applicable for humans.


Given the enormous differences between the biology of humans and the biology of common model organisms like mice, combined with the higher degree of biological complexity as it pertains to ageing vs. single diseases, we can expect the clinical translation failure rate in the Longevity Industry to be much higher than the already-enormous failure rate in traditional BioTech.

New approaches to scientific due diligence and the validation of results for longevity-focused companies are needed to ensure protection against company and industry devaluation. However, there are a number of existing approaches that can be used by investors to de-risk longevity investments.

The use of biomarkers of aging and longevity constitutes the most market-ready and validated means of proving efficacy in humans. It can also serve as a basis for demonstrating human-validated results by longevity companies and startups. A wide array of single biomarkers and panels of biomarkers of Longevity exists in a market-ready form, and should be adopted by longevity investors for due-diligence in order to create a more modern, sophisticated and robust method of preliminary validation of therapeutic safety and efficacy.

In addition to biomarkers, there is also a large number of other modern approaches capable of providing preliminary indicators of human validation. They can be used to create a coordinated framework which will provide investors with greater confidence in the likelihood of clinical translatability. These include:

- In silico human modeling
- In vitro tests using human cells and tissues
- Human-animal chimeras (e.g., human-mouse chimeras) for safety, toxicity and efficacy testing. This approach is already common in immuno-oncology research, and a wide array of validated approaches can be applied for testing of aging-focused interventions.
- In vivo administration of sub-therapeutic doses using microfluidic chips (i.e., in vitro “skin-on-a-chip” testing).



Longevity Finance: Big Data Analytics Dashboard



Longevity Finance Big Data Analytics Dashboard

Market Intelligence

Longevity Finance Market Intelligence

- SWOT Analysis
- Interactive Mindmaps
- Market Intelligence

View More

Dashboard Parameters

| | | |
|-------------------------|-------------|-----------|
| COMPANY TYPES | COMPANIES | COUNTRIES |
| 5 | 298 | 30 |
| ASSETS UNDER MANAGEMENT | DATA POINTS | SECTORS |
| 15 | 114061 | 50 |

View More

Financial Institutions Digest

INVESTMENT DIGEST

LONGEVITY FINANCIAL INSTITUTIONS 2021

View More

Longevity Finance Market Intelligence

- Pre-Subscribe for Beta
- Sponsorship Opportunities
- Request Custom Analytics

Search Engine

Longevity Finance Search Engine

- Interactive Database
- Dynamic Network Diagrams
- Competitor Search

View More

Interactive Database

View More

Interactive Charts

Assets Under Management by major geographic regions, \$ billions

| | |
|----------------|----|
| North America | 33 |
| Western Europe | 28 |
| Asia Pacific | 23 |
| Other | 14 |

2018
Total, trillions: 104

View More

Public Financial Institutions

Cumulative Capitalization Dynamics in 2016-2020


View More

Longevity Finance Search Engine

- Personalities
- Corporations
- Startups
- Investors

<https://www.aginganalytics.com/finance-dashboard>

Deep Pharma Big Data Analytics Dashboard



Deep Pharma Intelligence Big Data Analytics Dashboard is one of the analytical platforms developed by Deep Knowledge Group.

Its main goal is to provide Big Data-based analytical insights, as well as being a Longevity-focused database for institutional and non-institutional investors. It also allows creation of different types of investment portfolios and assesses them with built-in tools provided by the platform.

www.platform.dkj.global/dashboards/ai-for-drug-discovery

Longevity Investment: Big Data Analytics Dashboard



Longevity Investment Big Data Analytics Dashboard

Market Intelligence

Longevity Investment Market Intelligence

Major Trends

Network Diagrams

Interactive MindMaps

Interactive Mindmaps



View More

Dashboard Parameters

DATA POINTS

814090

PERSONALITIES

16107

COMPANIES

19603

INVESTORS

9007


SECTORS

14

SUBSECTORS

140

Dynamic Industry Charts



View More

Longevity Investment Market Intelligence

SWOT Analysis

FAQ & Tutorials

Register Free Account

Send Us Feedback

Search Engine

Longevity Investment Ecosystem Investors

Investor Portfolio Search

Investor Competitors Search

Investor Search


Investor & Company Advanced Search



Find Investors

Find Companies

Competitor Search



Company Competitors

Investor Competitors

Interactive Network Diagrams



View More

Longevity Investment Ecosystem Companies


Company Investor Search

Company Competitors Search

Entrepreneur Search

Welcome There!

www.longevity-book.com



Longevity Industry 1.0

Defining the Biggest and Most
Complex Industry in Human History

PART I. Longevity Industry Mega-Complexity

PART II. Longevity Policy and Governance


PART III: The Longevity Financial Industry

Novel Longevity Derivatives and Health as New Wealth


- **The Increasing Role of Longevity in Global Finance**
- Longevity Embraced by the World's Biggest Financial Corporations: Investment Banks, Insurance Companies, Asset Management Firms
- Longevity Derivatives: New Business Models and Novel Financial Instruments Tied to the Rising Longevity Industry
- AgeTech, WealthTech, FinTech
- Why Traditional BioTech Analytics Fails Against the Longevity Industry's Extreme Complexity

PART IV. Longevity Industry (Science and Biomedicine)

Global Industrialization of Longevity



Longevity Industry 1.0
Defining the Biggest and Most
Complex Industry in Human History



Longevity Industry 2.0
DeepTech Engineering The Accelerated
Trajectory of Human Longevity
The Blueprint and Pathway from 1.0 to 2.0



AGING ANALYTICS AGENCY

Longevity Investment Digest: www.aginganalytics.com/investment-digest

E-mail: info@aginganalytics.com

Website: www.aginganalytics.com

Aging Analytics Agency (AAA) Disclaimer.

The information and opinions in this report were prepared by Aging Analytics Agency. The information herein is believed by AAA to be reliable but AAA makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. AAA may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of AAA may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of AAA and are subject to change without notice. AAA has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.